In 03/20 Omeros shareholders were momentarily excited by its initial phase 3 stem cell TMA data readout.
Overall that is one ugly chart, but it tells a story. Omeros' price chart for the last year, below, paints the picture: Data by YCharts During that time frame its chart has zigged and zagged moving inconclusively in a general range of $10-$20. I have been an Omeros bull for several years. However, that would be a bit disingenuous. I might crow about the fact that I published this article when Omeros was trading ~$10 and it has since doubled. I am bullish per my 10/26/20 article, "Omeros: Golden Opportunity With COVID-19 Kicker". Shareholders who have suffered from the whiplash may wonder what's next for this zigzagging investment which has so much difficulty in choosing between a bull or a bear thesis. Omeros' recent bull run is fully justified by its unfolding prospects.Īfter two recent quick and dirty failed feints to the high side, Omeros has recently soldiered back to its long-term resistance price of ~$20. There is plenty of opportunity left in Omeros. I explain why I am quite bullish on Omeros, albeit recognizing that it may experience a respite after its recent bull run. In this article I will describe Omeros' experience as it follows a similar path. I reported on Acadia recently in " Acadia: Waxing And Waning Into A Big PDUFA". Omeros ( NASDAQ: OMER) is running neck and neck with its fellow near term PDUFA peer Acadia ( ACAD) for top spot in my speculative biotech portfolio.
0 kommentar(er)
